An immune system defect makes affected individuals vulnerable to severe viral diseases such as influenza or COVID-19. It is caused by the body’s own antibodies, which inhibit important defense proteins known as type I interferons. UZH researchers have now generated “decoy molecules” that intercept these autoantibodies and restore the immune defense – the foundation for a possible new therapy.